SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, long-acting glucocorticoids (GCs) and/or multiple daily dose short-acting GCs are historically suggested to disease management. However, these treatment strategies are generally associated with GC overexposure, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeoli, Chiara, Ferrigno, Rosario, Angellotti, Domenico, Iacuaniello, Davide, Pivonello, Claudia, Negri, Mariarosaria, Di Gennaro, Gilda, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552856/
http://dx.doi.org/10.1210/js.2019-SUN-358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552856/
http://dx.doi.org/10.1210/js.2019-SUN-358

Ejemplares similares